Rising to the Challenge:
The Evolving Landscape of Maintenance Therapy in Ovarian Cancer

Released On
June 22, 2021

Expires On
December 22, 2021

Media Type

Completion Time
45 minutes

Case Management, Endocrinology, Genetics, Hematology-Oncology, Obstetrics & Gynecology, Other

Menopause, Pharmacology, Oncology

Scroll to the Bottom of this Information to Begin this Course

This educational activity is jointly provided by Postgraduate Institute for Medicine and Spire Learning.


This activity is supported by an educational grant from Tesaro, Inc., a GSK Company.

Credit Available

  • Physicians — maximum of 0.75 AMA PRA Category 1 Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for medical oncologists and gynecologic oncologists, and other HCPs who provide care for patients with ovarian cancer.

Program Overview

The landscape of maintenance treatment options for ovarian cancer has been rapidly expanding and continues to evolve as new data emerge. Maintenance therapy with poly(ADP-ribose) polymerase (PARP) inhibitors and bevacizumab has demonstrated improvements in progression-free survival. A recent trial showed that maintenance therapy involving a PARP inhibitor improved overall survival in patients with platinum-sensitive recurrent ovarian cancer associated with BRCA1/2 mutations. In this enduring activity, an expert will examine relevant advances in genetic biomarker testing to individualize therapy, assess recent efficacy and safety data related to PARP inhibitors and bevacizumab maintenance therapy, and review strategies to effectively prevent and manage adverse effects.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • SUMMARIZE the rationale for maintenance therapy in ovarian cancer
  • EVALUATE the efficacy and safety results of available maintenance therapies in ovarian cancer to tailor treatment recommendations
  • IMPLEMENT individualized strategies to effectively manage and prevent adverse events for ovarian cancer maintenance therapy
  • UTILIZE genetic biomarker testing for individualized treatment and prevention recommendations for women with or at risk for ovarian cancer


Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Spire Learning. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Conflicts of Interest Disclosure Policy

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The planning staff and content managers hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.


Ursula A. Matulonis, MD

  • Consulting Fees: Merck, NextCure, and Novartis.

Planners and Managers

Postgraduate Institute for Medicine:
The following planners and managers have nothing to disclose: Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, MBA, MSN, RN; and Amanda Glazar, PhD, CHCP.

Spire Learning:
Chris Washburn, PhD: None.

Chad Thompson and Mary Simmons have no relevant financial relationships with any commercial interests.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. Here is the process for participants to receive CME credit:

  1. Read the CME/CE information and faculty disclosures.
  2. Log in to participate in the activity.
  3. Complete the Pretest.
  4. You may move forward through the panel discussion; however, you may not go back to change answers or review video files/content until you finish the presentation.
  5. To receive a CME/CE certificate, you must complete the activity Post-test and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.
Certificates will be emailed to the participant.


Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Privacy Policy

Spire Learning, LLC is committed to protecting the privacy of personal information from our participants and educational collaborators. Spire maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of personal information.

Collection and Use of Your Personal Information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected, retained, and used by Spire Learning, LLC to continuously improve the learning experience.

Spire Learning, LLC will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Spire will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws.

Copyright Information

Copyright © 2021 by Spire Learning, LLC, and its Licensors. All rights reserved. No part of this publication or activity may be reproduced or transmitted in any form, by any means, without prior written permission of Spire Learning, LLC. Spire Learning, LLC, and Postgraduate Institute for Medicine will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication or activity, including any claims related to the products, drugs, or services mentioned herein.